O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas

O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy w

(2012) Emmanuèle Lechapt-Zalcman et al.   CANCER

Resveratrol Enhances the Antitumor Effects of Temozolomide in Glioblastoma via ROS-dependent AMPK-TSC-mTOR Signaling Pathway

(2012) Yuan Yuan et al.   CNS Neuroscience & Therapeutics

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR

(2012) Annette Håvik et al.   Journal of Translational Medicine

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia

(2011) Bruno C. Medeiros et al.   AMERICAN JOURNAL OF HEMATOLOGY

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours

(2011) H A Tawbi et al.   BRITISH JOURNAL OF CANCER

Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision Repair

(2011) E. M. Goellner et al.   CANCER RESEARCH

Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles

(2011) Steve Quiros et al.   CELL CYCLE

Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sezary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins

(2011) C. Querfeld et al.   CLINICAL CANCER RESEARCH

Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy

(2011) Chien-Ju Lin et al.   FREE RADICAL BIOLOGY AND MEDICINE

Predictive impact of MGMT promoter methylation in glioblastoma of the elderly

(2011) Guido Reifenberger et al.   INTERNATIONAL JOURNAL OF CANCER

Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells

(2011) Ryuichi Kanai et al.   JNCI-Journal of the National Cancer Institute

Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma

(2010) Hiroaki Toshimitsu et al.   ANNALS OF SURGICAL ONCOLOGY

The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway

(2010) Michael R. Lieber   Annual Review of Biochemistry

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

(2010) J C Hassel et al.   BRITISH JOURNAL OF CANCER

Dose-dense temozolomide regimens

(2010) Bart Neyns et al.   CANCER

Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

(2010) Bernd Kaina et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma

(2010) Markus Christmann et al.   INTERNATIONAL JOURNAL OF CANCER

O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma

(2010) Yukihiko Sonoda et al.   International Journal of Clinical Oncology

A Phase I Trial of Tipifarnib With Radiation Therapy, With and Without Temozolomide, for Patients With Newly Diagnosed Glioblastoma

(2010) Phioanh Leia Nghiemphu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport Chain

(2010) Claudia R. Oliva et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma

(2010) Michael Brada et al.   JOURNAL OF CLINICAL ONCOLOGY

Purified human BRCA2 stimulates RAD51-mediated recombination

(2010) Ryan B. Jensen et al.   NATURE

Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA

(2010) Jie Liu et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action

(2010) Roberto Bei et al.   Recent Patents on Anti-Cancer Drug Discovery

The potential role and application of PARP inhibitors in cancer treatment

(2009) A. J. Chalmers   BRITISH MEDICAL BULLETIN

The safety of temozolomide in the treatment of malignancies

(2009) Van Anh Trinh et al.   Expert Opinion On Drug Safety

Interactions of Human Mismatch Repair Proteins MutSα and MutLα with Proteins of the ATR-Chk1 Pathway

(2009) Yiyong Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics ofTrans-resveratrol Following Repeated Administration in Healthy Elderly and Young Subjects

(2009) Teresa Nunes et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells

(2009) Li-Chen Chou et al.   JOURNAL OF GASTROENTEROLOGY

A quantum chemical study of repair of O6-methylguanine to guanine by tyrosine: Evaluation of the winged helix-turn-helix model

(2009) Saumya Tiwari et al.   JOURNAL OF MOLECULAR MODELING

Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

(2009) Luis Almeida et al.   MOLECULAR NUTRITION & FOOD RESEARCH

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma

(2009) Jennifer A. Quinn et al.   NEURO-ONCOLOGY

Mechanism of Eukaryotic Homologous Recombination

(2008) Joseph San Filippo et al.   Annual Review of Biochemistry

Alterations in S-adenosylhomocysteine metabolism decrease O6-methylguanine DNA methyltransferase gene expression without affecting promoter methylation

(2008) Marina Hermes et al.   BIOCHEMICAL PHARMACOLOGY

Homologous recombination in DNA repair and DNA damage tolerance

(2008) Xuan Li et al.   CELL RESEARCH

Recent Approaches to Improve the Antitumor Efficacy of Temozolomide

(2008) Lucio Tentori et al.   CURRENT MEDICINAL CHEMISTRY

Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

(2008) Monika E. Hegi et al.   JOURNAL OF CLINICAL ONCOLOGY

CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo

(2008) S.-W. Wang et al.   MOLECULAR CANCER THERAPEUTICS

New (alternative) temozolomide regimens for the treatment of glioma

(2008) Wolfgang Wick et al.   NEURO-ONCOLOGY

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

(2008) Gaspar J. Kitange et al.   NEURO-ONCOLOGY